Form D · Pharmaceuticals
BioSplice Therapeutics, Inc.
San Francisco, CA · CIK 0001848940
Offering snapshot reported Aug 24, 2022 · SEC filing
- Reported sold
- Yet to sell Indefinite offering
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 24, 2022 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Mar 3, 2021 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-456870
Source: Form D, filed Aug 24, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Darrin Beaupre | Executive |
| Scott Bulcao | Executive |
| Troy Cox | Director |
| Joy Ghosh | Director |
| Susannah Gray | Director |
| Erich Horsley | Executive |
| Osman Kibar | Director |
| Karen Mc Ginnis | Director |
| Arman Oruc | Executive |
| Kyle Rasbach | Director |
| Gur Roshwalb | Director |
| Cevdet Samikoglu | Director, Executive |
| Yusuf Yazici | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
9360 Towne Centre Drive
San Francisco, CA, 92121
San Francisco, CA, 92121